QIAGEN plans automated tuberculosis testing workflow for late 2027
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing
May 7, 2026 6:00 AM EDTAmbition to support high-throughput laboratories in efficiently scaling latent tuberculosis (TB) screening as testing volumes continue to grow Fully automated workflow targeted for late 2027 launch integrates QuantiFERON test, Diasorin LIAISON systems, and purpose-built end-to-end automation from new Inpeco partnership AI-enabled risk stratification tool for TB progression targeted for late 2027 launch, designed to support all QuantiFERON customers with informed clinical decision-making for patient care QIAGEN and Diasorin driving LIAISON adoption with LIAISON QuantiFERON-TB Gold Plus II,... More
